ProPhase Labs, Inc. (PRPH) CFO Sells $824,828.30 in Stock
ProPhase Labs, Inc. (NASDAQ:PRPH) CFO Robert V. Cuddihy, Jr. sold 358,621 shares of ProPhase Labs stock in a transaction on Friday, September 29th. The shares were sold at an average price of $2.30, for a total transaction of $824,828.30. Following the completion of the sale, the chief financial officer now directly owns 132,703 shares of the company’s stock, valued at approximately $305,216.90. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of ProPhase Labs, Inc. (PRPH) opened at 2.05 on Thursday. The company has a 50-day moving average of $2.22 and a 200 day moving average of $2.08. The firm has a market cap of $33.14 million, a P/E ratio of 0.85 and a beta of 0.02. ProPhase Labs, Inc. has a 52-week low of $1.78 and a 52-week high of $2.45.
ProPhase Labs (NASDAQ:PRPH) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.09) earnings per share for the quarter. The firm had revenue of $1.91 million during the quarter. ProPhase Labs had a return on equity of 54.87% and a net margin of 270.98%.
ProPhase Labs announced that its Board of Directors has authorized a stock buyback program on Tuesday, August 15th that permits the company to repurchase 4,000,000 outstanding shares. This repurchase authorization permits the company to purchase shares of its stock through a tender offer. Shares repurchase programs are usually an indication that the company’s leadership believes its shares are undervalued.
TRADEMARK VIOLATION NOTICE: “ProPhase Labs, Inc. (PRPH) CFO Sells $824,828.30 in Stock” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/05/prophase-labs-inc-prph-cfo-sells-824828-30-in-stock.html.
Separately, ValuEngine downgraded shares of ProPhase Labs from a “hold” rating to a “sell” rating in a research report on Thursday.
ProPhase Labs Company Profile
ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.
Receive News & Stock Ratings for ProPhase Labs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs Inc. and related stocks with our FREE daily email newsletter.